Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASSO: Allopurinol Safety and Outcomes in Gout
NCT01391325Phase 4Completed
- Sponsor
- Ardea Biosciences, Inc.
- Start
- Jul 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, open-label, single-arm trial of allopurinol in gout, sponsored by Ardea Biosciences, Inc. Primary endpoint: Safety of Allopurinol at 6 months. Started Jul 2011; status: completed.
02
Drugs
allopurinol
03
Conditions
gout
Beyond the preview
Go deeper on NCT01391325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01391325.